Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Logitech International SA (LOGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Logitech International SA — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Logitech International SA trades at $97.21 (market cap $13.85B). The key difference: Logitech International SA is far larger — about 3.1× ACADIA Pharmaceuticals Inc.'s market cap, and Logitech International SA pays a 1.75% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | LOGI | |
|---|---|---|
Market Cap | $4.49B | $13.85B |
Sector | Health | Technology |
52-Week High | $28.06 | $126.69 |
52-Week Low | $20.06 | $85.84 |
Enterprise Value | $3.69B | $12.20B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Logitech (LOGI) trades at $97.11, up 3.31% with strong profitability metrics including 43.2% gross margin and 32.78% ROE. The stock shows bearish technical signals despite recent earnings beats, with Q1 2026 EPS of $1.13 exceeding expectations. Recent developments include new gaming partnerships and product launches like the G3 Series and Mobi Fold mouse. Cash flow trends show operational strength with $843M generated in 2025, though net cash flow was slightly negative at -$18M.
Logitech presents a mixed outlook with robust fundamentals offset by technical weakness. The 26% upside to consensus price target of $121.33 offers potential, but bearish moving averages and competitive pressures in peripherals market pose risks. Enterprise momentum and AI-enabled products provide growth catalysts, though investor sentiment remains divided with equal buy/sell analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
